americanpharmaceuticalreviewDecember 05, 2018
Tag: ChemomAb , Dr. Stephen Squinto , clinical trial , biotech and pharmaceutical
ChemomAb announced the appointment of Dr. Stephen Squinto as the company’s chairman of the board.
In this role, Dr. Squinto will help guide the company as it continues the clinical development of its lead compound towards advanced clinical trials.
"Dr. Squinto has led numerous biotech and pharmaceutical firms and his vast experience will be invaluable to ensuring that the company continues to bring its lead candidate through clinical trials in several fibrotic indications," said Dr. Adi Mor, CEO and CSO of ChemomAb.
Dr. Squinto is a Venture Partner with OrbiMed who brings over 25 years of biotechnology industry experience to ChemomAb. After completing both his undergraduate and doctoral work at Loyola College of Chicago, Dr. Squinto started his career at Regeneron Pharmaceuticals while holding two separate academic positions at Tulane and LSU’s Medical Schools. He was a co-founder of Alexion Pharmaceuticals and served as their Executive Vice President, Chief Global Operations Officer and Global Head of Research and Development. His work has led to over 70 scientific papers in the fields of gene regulation, growth factor biology and gene transfer, and he is the recipient of numerous honors and awards from academic and professional organizations for his scientific work.
"I was drawn to ChemomAb because I believe the company has found a novel mechanism of action that plays an important role in fibrosis processes. It’s lead drug is showing promising results that will now be tested in clinical trials," said Dr. Squinto. "The team has done an impressive job in advancing the company and I look forward to supporting their continued success."
-----------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: